8-K
filed January 2, 2026, 6:59 PM ET
ticker ISPC
CIK 0001558569
other material
confidence high
sentiment neutral
materiality 0.60
iSpecimen raises $5.5M via Series C Convertible Preferred Stock at $800/share
iSpecimen Inc.
- Issued 6,875 shares of Series C Convertible Non-Voting Preferred at $800/share for $5.5M aggregate.
- Conversion price set at 85% of prior day's closing price, floor at $0.0681 per share.
- Shares are senior to common on liquidation and carry no voting rights; registration rights granted.
- E.F. Hutton acted as exclusive placement agent; lock-up agreements with officers/directors for 180 days.
Key facts
Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
iSpecimen Inc. issued 6,875 shares of Series C Preferred Stock of preferred stock to certain accredited investors for aggregate purchase price of $5.5 million.
- Security
- preferred stock
- Shares
- 6,875 shares of Series C Preferred Stock
- Purchaser
- certain accredited investors
- Consideration
- aggregate purchase price of $5.5 million
Exact text from the filing
“Floor Price”). Pursuant to the Purchase Agreement, on December 31, 2025, the Company issued and sold 6,875 shares of Series C Preferred Stock for an aggregate purchase price of $5.5 million at the closing (the “Closing”). In connection with the Purchase Agreement, the Company also entered into a Registration Rights Agreement with the Investors (the “Registration
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
iSpecimen Inc.: Company filed a Certificate of Designation establishing the Series C Convertible Non-Voting Preferred Stock (effective 2025-12-30).
- Change
- charter amendment
- Effective
- 2025-12-30
Exact text from the filing
On December 30, 2025, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series C Convertible Non-Voting Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware, establishing the rights, preferences, privileges and limitations of such Series C Preferred Stock.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
iSpecimen Inc. entered into Placement Agent Agreement with E.F. Hutton & Co. valued at Placement Agent agreed to act as the Company’s exclusive placement agent in connection with the Offe (effective 2025-12-30).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- E.F. Hutton & Co.
- Value
- Placement Agent agreed to act as the Company’s exclusive placement agent in connection with the Offe
- Effective
- 2025-12-30
Exact text from the filing
In addition, in connection with the Offering, the Company entered into a Placement Agent Agreement, dated December 30, 2025 (the “Placement Agent Agreement”), with E.F. Hutton & Co. (the “Placement Agent”), pursuant to which the Placement Agent agreed to act as the Company’s exclusive placement agent in connection with the Offering, subject to the terms and conditions set forth therein.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
iSpecimen Inc. entered into Registration Rights Agreement with the Investors valued at Company agreed to provide certain registration rights with respect to the resale of the Conversion S (effective 2025-12-30).
- Action
- entry
- Counterparty
- the Investors
- Value
- Company agreed to provide certain registration rights with respect to the resale of the Conversion S
- Effective
- 2025-12-30
Exact text from the filing
In connection with the Purchase Agreement, the Company also entered into a Registration Rights Agreement with the Investors (the “Registration Rights Agreement”), pursuant to which the Company agreed to provide certain registration rights with respect to the resale of the Conversion Shares, and agreed to file an initial registration statement within certain time periods as set forth in the Registration Rights Agreement to register the Conversion Shares.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
iSpecimen Inc. entered into Securities Purchase Agreement with certain accredited investors valued at 6,875 shares of Series C Convertible Non-Voting Preferred Stock having a stated value of $1,000 per (effective 2025-12-30).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain accredited investors
- Value
- 6,875 shares of Series C Convertible Non-Voting Preferred Stock having a stated value of $1,000 per
- Effective
- 2025-12-30
Exact text from the filing
On December 30, 2025, iSpecimen Inc., a Delaware corporation (Nasdaq: ISPC) (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which the Company agreed to sell, and the Investors agreed to purchase, 6,875 shares of the Company’s newly-designated Series C Convertible Non-Voting Preferred Stock, par value $0.0001 per share (the “Series C Preferred Stock”), having a stated value of $1,000 per share, at a purchase price of $800 per share.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.